Shortly after the FDA approved the much-anticipated Alzheimer’s drug Leqembi as an intravenous infusion, Eisai announced positive results from a study examining a subcutaneous formulation of Leqembi.
At the Alzheimer’s Association International Conference 2023, Eisai researchers presented a study comparing intravenous and subcutaneous dosing of Leqembi. The analysis found that a subcutaneous injection of Leqembi resulted in around 50% bioavailability compared to the IV form.
According to Eisai, these “promising” findings support the potential for a subcutaneous version of the Alzheimer’s medication, which could allow for broader usage given that it would not need to be administered at infusion centers like the IV formulation. Read the full article published by Fierce Pharma here.